文献速递乳腺癌

阿贝西利联合氟维司群改善内分泌治疗后进展的HR阳性/HER2阴性晚期乳腺癌总生存:MONARCH 2研究

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2020-01-01

MONARCH 2是一项全球随机双盲3期试验,比较阿贝西利联合氟维司群与安慰剂联合氟维司群治疗内分泌治疗后进展的HR阳性/ERBB2阴性晚期乳腺癌。

要点

  • 阿贝西利联合氟维司群显著改善总生存,中位OS延长9.4个月(46.7 vs 37.3个月)。
  • 内脏转移和原发内分泌耐药亚组获益更明显(HR分别为0.675和0.686)。
  • 至后续化疗时间和无化疗生存期均显著延长(50.2 vs 22.1个月;25.5 vs 18.2个月)。

核心结论

  • 阿贝西利联合氟维司群在HR阳性/ERBB2阴性晚期乳腺癌内分泌治疗后进展患者中带来统计学显著且临床意义的总生存获益,中位OS延长9.4个月。
  • 无论绝经状态如何,总生存获益在各分层因素中一致。

研究设计与样本

  • MONARCH 2为全球、随机、安慰剂对照、双盲3期试验,纳入669例HR阳性/ERBB2阴性晚期乳腺癌患者,按2:1随机接受阿贝西利或安慰剂(150 mg每12小时)联合氟维司群(500 mg)。
  • 患者为绝经前/围绝经期(接受卵巢抑制)或绝经后女性,在内分泌治疗期间进展;2014年8月7日至2015年12月29日入组。

主要发现

  • 内脏转移患者HR 0.675(95%CI 0.511-0.891);原发内分泌耐药患者HR 0.686(95%CI 0.451-1.043)。
  • 至第二次疾病进展中位时间:23.1个月 vs 20.6个月;至化疗时间中位:50.2个月 vs 22.1个月;无化疗生存期中位:25.5个月 vs 18.2个月,均具统计学显著改善。
  • 未观察到阿贝西利新的安全性信号。

关键数值与推荐

  • 内脏转移亚组HR 0.675(95%CI 0.511-0.891);原发内分泌耐药亚组HR 0.686(95%CI 0.451-1.043)。
  • 至化疗时间中位50.2个月 vs 22.1个月;无化疗生存期中位25.5个月 vs 18.2个月。

临床怎么用

  • 对于内分泌治疗后进展的HR阳性/ERBB2阴性晚期乳腺癌患者,可考虑阿贝西利联合氟维司群方案,无论绝经状态。
  • 该方案显著延迟后续化疗需求,可作为内分泌治疗后进展患者的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Statistically significant overall survival (OS) benefits of CDK4 and CDK6 inhibitors in combination with fulvestrant for hormone receptor (HR)-positive, ERBB2 (formerly HER2)-negative advanced breast cancer (ABC) in patients regardless of menopausal status after prior endocrine therapy (ET) has not yet been demonstrated. OBJECTIVE: To compare the effect of abemaciclib plus fulvestrant vs placebo plus fulvestrant on OS at the prespecified interim of MONARCH 2 (338 events) in patients with HR-positive, ERBB2-negative advanced breast cancer that progressed during prior ET. DESIGN, SETTING, AND PARTICIPANTS: MONARCH 2 was a global, randomized, placebo-controlled, double-blind phase 3 trial of abemaciclib plus fulvestrant vs placebo plus fulvestrant for treatment of premenopausal or perimenopausal women (with ovarian suppression) and postmenopausal women with HR-positive, ERBB2-negative ABC that progressed during ET. Patients were enrolled between August 7, 2014, and December 29, 2015. Analyses for this report were conducted at the time of database lock on June 20, 2019. INTERVENTIONS: Patients were randomized 2:1 to receive abemaciclib or placebo, 150 mg, every 12 hours on a continuous schedule plus fulvestrant, 500 mg, per label. Randomization was stratified based on site of metastasis (visceral, bone only, or other) and resistance to prior ET (primary vs secondary). MAIN OUTCOMES AND MEASURES: The primary end point was investigator-assessed progression-free survival. Overall survival was a gated key secondary end point. The boundary P value for the interim analysis was .02. RESULTS: Of 669 women enrolled, 446 (median [range] age, 59 [32-91] years) were randomized to the abemaciclib plus fulvestrant arm and 223 (median [range] age, 62 [32-87] years) were randomized to the placebo plus fulvestrant arm. At the prespecified interim, 338 deaths (77% of the planned 441 at the final analysis) were observed in the intent-to-treat population, with a median OS of 46.7 months for abemaciclib plus fulvestrant and 37.3 months for placebo plus fulvestrant (hazard ratio [HR], 0.757; 95% CI, 0.606-0.945; P = .01). Improvement in OS was consistent across all stratification factors. Among stratification factors, more pronounced effects were observed in patients with visceral disease (HR, 0.675; 95% CI, 0.511-0.891) and primary resistance to prior ET (HR, 0.686; 95% CI, 0.451-1.043). Time to second disease progression (median, 23.1 months vs 20.6 months), time to chemotherapy (median, 50.2 months vs 22.1 months), and chemotherapy-free survival (median, 25.5 months vs 18.2 months) were also statistically significantly improved in the abemaciclib arm vs placebo arm. No new safety signals were observed for abemaciclib. CONCLUSIONS AND RELEVANCE: Treatment with abemaciclib plus fulvestrant resulted in a statistically significant and clinically meaningful median OS improvement of 9.4 months for patients with HR-positive, ERBB2-negative ABC who progressed after prior ET regardless of menopausal status. Abemaciclib substantially delayed the receipt of subsequent chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02107703.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Sledge GW, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2020. PMID: 31563959. doi:10.1001/jamaoncol.2019.4782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。